Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib + aromatase inhibitor vs chemotherapy + endocrine therapy in elderly node-positive HR+/HER2- early breast cancer
ChiCTR2600129445Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ribociclib in breast cancer (2 arms), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: Invasive Disease-Free Survival. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600129445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129445.